Detailed Information on Publication Record
2023
In vitro biological activity of cobalt(II) complexes with salicylaldimine ligands in microbial and cancer cells
WILLIEM, Ereny S., Ahmed B. M. IBRAHIM, S. ABD ELKHALIK, Jaromír MAREK, S. M. ABBAS et. al.Basic information
Original name
In vitro biological activity of cobalt(II) complexes with salicylaldimine ligands in microbial and cancer cells
Authors
WILLIEM, Ereny S., Ahmed B. M. IBRAHIM (guarantor), S. ABD ELKHALIK, Jaromír MAREK (203 Czech Republic, belonging to the institution) and S. M. ABBAS
Edition
Future Medicinal Chemistry, Newlands Press Ltd, 2023, 1756-8919
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30107 Medicinal chemistry
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.200 in 2022
RIV identification code
RIV/00216224:14310/23:00133366
Organization unit
Faculty of Science
UT WoS
001048093100001
Keywords in English
anionic ligands; breast cells; Candida albicans; Schiff bases; Staphylococcus aureus; tetrahedral
Tags
International impact, Reviewed
Změněno: 27/10/2024 15:25, Ing. Martina Blahová
Abstract
V originále
Background: More studies using cobalt complexes as drugs are needed. Results: The drug action of two cobalt salicylaldimines was determined. The complexes and amphotericin B (20 mg/ml) inhibited Candida albicans at 9–15 and 21 mm. This concentration of both ligands inhibited Staphylococcus aureus at 10 mm and one ligand inhibited Escherichia coli at 9 mm, but the complexes and ampicillin inhibited four bacteria at 9–20 and 21–26 mm. The ligands were inactive against cancer and normal cells, but the complexes and doxorubicin provided IC50 values of 28.18–54.19 and 9.66 μM against MCF-7 cells and 15.76–20.49 and 36.42 μM against BHK cells. Conclusion: The ligands' activity was much improved by complexation, although they remained substandard.
Links
90242, large research infrastructures |
|